Contraception Drug Pipeline — PatSnap Eureka
Non-Hormonal Contraception: Male, Female & Progesterone Receptor Modulator Pipeline
From sAC inhibitors and RARA antagonists for male contraception to SPRM pharmacology and antibody-based female approaches — explore the patent and literature signals shaping the next generation of contraceptive R&D.
Eight Approaches Across the Contraception Drug Pipeline
Retrieved patent and literature records map the contraception pipeline across hormonal and non-hormonal strategies for both sexes, with the progesterone receptor space representing the most patent-dense modality in the dataset.
sAC & RARA Small-Molecule Programs
Soluble adenylyl cyclase (sAC; gene ADCY10) is proposed by Weill Cornell Medicine as an on-demand target that could immobilize sperm acutely without suppressing spermatogenesis. Separately, RARA antagonists including BMS-189453 have been validated in murine models by the University of Minnesota. Both programs are currently at the preclinical stage.
Preclinical — Lead OptimizationAnti-Sperm Antibodies & MB66 Vaginal Film
ZabBio's MB66 multipurpose prevention vaginal film targeting CD52g via the H6-3C4 antibody has completed Phase 1 clinical testing and is described as effective and safe in women. The University of North Carolina engineered highly multivalent IgGs (HM-IgGs) with 6–10 Fab arms achieving >99.9% reduction in progressively motile sperm in sheep vaginal studies at 33 µg doses.
Phase 1 Complete (MB66)SPRMs, Antiprogestins & Mesoprogestins
The most patent-dense modality in the dataset. Ulipristal acetate is licensed for emergency contraception (30 mg, up to 120 hours post-intercourse) and for managing abnormal uterine bleeding in leiomyoma patients. Asoprisnil demonstrates Phase 2+ clinical evidence for amenorrhea induction and leiomyoma volume reduction. Mesoprogestins (J867, J912, J956, J1042) represent a mechanistically distinct intermediate PR state.
Approved / Phase 2+ (Asoprisnil)GnRH Peptide Nanoparticle Vaccines
The University of Queensland describes a polyacrylate-GnRH peptide nanoparticle vaccine inducing high IgG titers with efficacy after subcutaneous and oral administration in mice and pigs. Panjab University reviews immunocontraceptive approaches targeting sperm antigens and gonadotropin-releasing hormone. Both programs remain at the preclinical animal stage.
Preclinical — Animal ModelsProgestin + Androgen Combination Approaches
Exogenous progestins suppress the HPG axis to reduce testicular testosterone and spermatogenesis, with androgen replacement to maintain male physiology. The 2022 NIH/NICHD paper references completed efficacy studies confirming effectiveness and reversibility, with ongoing development of long-acting injectables, transdermal gels, and novel dual androgenic/progestational androgens.
Efficacy Trials CompletedFollicle Rupture Inhibitors & AMH Signaling
Northwestern University's Drosophila ex vivo follicle rupture assay screened 1,172 FDA-approved drugs, identifying six compounds with dose-dependent inhibition of follicle rupture. Two active Italian patents from inventor Antonio La Marca propose novel uses of anti-Müllerian hormone (AMH) for fertility regulation — the only active female contraceptive patents by a non-corporate inventor in the dataset.
Screening / Early PreclinicalFrom Progesterone Receptor to Sperm Surface Antigens
The progesterone receptor (PR) is the most heavily addressed target in this dataset, appearing across at least 15 patent records and 8 academic papers. Retrieved patents from Schering AG, Bayer Schering Pharma, Allergan, Jenapharm, and Balance Pharmaceuticals collectively define the PR modulator landscape. Competitive antagonists acting below the ovulation-inhibiting dose prevent endometrial gland formation and implantation, while SPRMs such as asoprisnil achieve uterine-selective PR effects without suppressing ovulation. The Eastern Virginia Medical School patent specifically claims PR antagonist use to prevent oocyte fertilization without disrupting ovulation or cycle regularity — a mechanistically novel claim within this class.
Retinoic Acid Receptor Alpha (RARA) is validated genetically (knockout infertility phenotype) and pharmacologically via the BMS-189453 series. The University of Minnesota describes alpha-selective ligand structure-activity relationships. The target is male-specific for contraceptive application and currently preclinical. Soluble Adenylyl Cyclase (sAC / ADCY10) is essential for male fertility and proposed by Weill Cornell as an on-demand target — challenging the assumption that broad tissue expression precludes targeting by proposing acute rather than chronic administration. Learn more about IP analytics for target validation at PatSnap.
For female non-hormonal approaches, CD52g (a GPI-anchored glycoprotein abundant on human sperm) is targeted by the H6-3C4 antibody in ZabBio's MB66 platform. The prolactin receptor (PRLR) was targeted by neutralizing antibodies in an inactive Bayer EP patent, suggesting this line was explored but not pursued commercially. AMH receptor signaling appears in two active Italian patents as an emerging, under-elaborated direction. For life sciences research teams exploring these targets, PatSnap's life sciences intelligence platform provides deep patent and literature coverage.
Patent Activity & Pipeline Stage Distribution
Visualising the patent assignee landscape and clinical translation signals across contraceptive modalities identified in this dataset.
Patent Records by Assignee Cluster
Bayer/Schering lineage dominates with at least 12 patent records across 6 jurisdictions; Allergan holds 2; Jenapharm, Ligand, and La Marca hold 1–2 each.
Pipeline Stage Distribution Across Modalities
Of the eight modalities identified, two have approved products, one has completed Phase 1, one is Phase 2+, one has completed efficacy trials, and three remain preclinical/early-stage.
From Patent Filing to Clinical Evidence: Key Milestones
Retrieved results contain several identifiable clinical translation signals across the contraception drug pipeline dataset.
| Asset / Approach | Assignee / Institution | Modality | Stage Signal | Key Finding |
|---|---|---|---|---|
| Ulipristal acetate (CDB-2914) | Imperial College London; AIIMS | SPRM | Approved | 30 mg single dose; effective up to 120 hours post-intercourse; also approved for AUB in leiomyoma patients |
| MB66 Vaginal Film (H6-3C4 / CD52g) | ZabBio, Inc. | Anti-sperm antibody (MPT) | Phase 1 Complete | Phase 1 clinical testing complete; described as effective and safe in women; targets HIV-1, HSV-2, and sperm motility |
| Vaginal pH Modulator (lactic acid / citric acid / potassium bitartrate) | Midwestern University (review) | Non-hormonal vaginal | Approved | Described as recently approved; immobilizes sperm via alkaline semen neutralization |
| Asoprisnil | TAP Pharmaceutical Products | SPRM | Phase 2+ | Human data: amenorrhea induction and leiomyoma volume reduction at doses maintaining follicular-phase estrogen; high uterine selectivity |
| Progestin + Androgen (hormonal male) | NIH/NICHD; Harbor-UCLA | Hormonal male | Efficacy Trials | Previous efficacy studies confirm effectiveness and reversibility; ongoing long-acting injectable and transdermal gel formulation programs |
| RARA Antagonists (BMS-189453 series) | University of Minnesota | Non-hormonal male (small molecule) | Preclinical | Murine pharmacology validated; alpha-selective analogs BMS-189532 and BMS-189614 evaluated for dosing regimen effects |
| sAC Inhibitors (ADCY10) | Weill Cornell Medicine | Non-hormonal male (on-demand) | Lead Optimization | Proposed acute-acting on-demand mechanism; public-private drug discovery collaboration; preclinical lead optimization stage |
| GnRH Polyacrylate Nanoparticle Vaccine | University of Queensland | Immunocontraception | Preclinical Animal | High IgG titers; subcutaneous and oral administration efficacy in mice and pigs |
Track Contraception IP Across 100+ Patent Jurisdictions
PatSnap Eureka surfaces active, inactive, and pending filings with AI-powered claim analysis for your R&D team.
What the Patent Landscape Signals for R&D Teams
Key strategic takeaways derived from patent and literature signals in this dataset — relevant for business development, IP strategy, and target selection teams.
Freedom-to-Operate Opportunity in SPRM Space
The SPRM/antiprogestin IP landscape is largely dominated by Bayer/Schering legacy patents, most of which are now inactive, creating freedom-to-operate opportunity for new entrants developing next-generation selective PR modulators with improved tissue selectivity profiles — particularly compounds that dissociate contraceptive from abortifacient activity, a distinction explicitly claimed in multiple Schering DE patents.
Non-Hormonal Male: Scientifically Active, Commercially Nascent
Non-hormonal male contraception is the most scientifically active but least commercially advanced area in this dataset. sAC and RARA represent the two most evidence-supported small-molecule targets, both with academic-led preclinical programs requiring industry partnership for IND-enabling studies and formulation development. See how R&D teams use PatSnap to accelerate target-to-IND timelines.
Beyond Single-Target Contraception: Combination Paradigms
Multiple Schering AG IL-jurisdiction patents claim use of at least one compound with progesterone-antagonistic (PA) activity combined with at least one compound with antiestrogenic (AE) activity — each at sub-ovulation-inhibiting doses — for female contraception via receptivity inhibition rather than ovulation suppression. This combination approach is explicitly framed as mechanistically distinct from ovulation-based contraception.
A Balance Pharmaceuticals ES patent combines antiprogestational agents (including progesterone synthesis inhibitors) administered over a first period with a progestogen over a second period, targeting both contraception and benign gynaecological disorders including endometriosis, fibroids, and polycystic ovary syndrome (PCOS). Separately, Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France holds multiple IL and LU-jurisdiction patents on synergistic combinations pairing sulpiride (a prolactin-elevating benzamide) with synthetic progestogens — an unusual psychopharmacology-reproductive biology intersection.
A 2023 paper from ISF College of Pharmacy describes the recently FDA-approved estetrol-drospirenone (E4-DRSP) combination oral contraceptive containing estetrol (a natural fetal estrogen) and drospirenone (an anti-mineralocorticoid spironolactone derivative). Bayer Intellectual Property GmbH and Bayer Schering Pharma also hold IL-jurisdiction patents for multi-phase preparations based on natural estrogen combined with synthetic gestagen, signaling a direction toward reduced synthetic estrogen burden. For chemistry-focused teams, PatSnap's chemical intelligence platform supports formulation and structure-activity relationship analysis. Regulatory intelligence from the FDA and the EMA provides complementary approval context for these combination approaches.
ZabBio's MB66 platform represents the most strategically significant emerging direction: convergence of contraceptive and STI-prevention functions in a single vaginal film product targeting HIV-1, HSV-2, and sperm motility — a multipurpose prevention technology (MPT) approach combining immunological and contraceptive modalities in one asset. PatSnap's analytics platform enables teams to map MPT freedom-to-operate across biological and chemical modalities simultaneously.
Contraception Drug Pipeline — key questions answered
Retrieved literature identifies soluble adenylyl cyclase (sAC; gene ADCY10) and retinoic acid receptor alpha (RARA) as the two most evidence-supported small-molecule targets for non-hormonal male contraception. sAC is proposed as an on-demand target that could immobilize sperm without chronic suppression of spermatogenesis, while RARA antagonists such as BMS-189453 have been validated pharmacologically in murine models. Both programs are currently at the preclinical stage.
Antibody-based female non-hormonal contraception (ZabBio MB66) is the furthest-advanced non-hormonal, non-device approach in retrieved data, having completed Phase 1 clinical testing — representing a credible near-term asset for licensing or partnership in the reproductive health MPT space. The MB66 vaginal film targets the sperm surface antigen CD52g via the H6-3C4 antibody and is designed as a multipurpose prevention technology combining contraception with STI prevention.
SPRMs are defined as PR ligands exerting tissue-selective agonist, partial agonist, or antagonist effects depending on target tissue context. Full antiprogestins such as mifepristone act as competitive antagonists, while SPRMs such as ulipristal acetate and asoprisnil achieve tissue-selective effects — for example, asoprisnil shows high uterine selectivity with minimal effect on ovulation, inducing amenorrhea and reducing leiomyoma volume dose-dependently. Mesoprogestins represent a further subclass with dual agonist/antagonist PR activity stabilizing the receptor at an intermediate functional state.
The SPRM/antiprogestin IP landscape is largely dominated by Bayer/Schering legacy patents, most of which are now inactive, creating freedom-to-operate opportunity for new entrants developing next-generation selective PR modulators with improved tissue selectivity profiles, particularly compounds that dissociate contraceptive from abortifacient activity — a distinction explicitly claimed in multiple Schering DE patents. The corporate lineage of Schering AG, Bayer Schering Pharma, Bayer Pharma, Bayer Intellectual Property GmbH, and Bayer OY accounts for at least 12 patent records across IL, FI, DE, PT, EP, and AU jurisdictions.
Multiple academic papers explicitly describe ulipristal acetate (CDB-2914) as licensed for emergency contraception (30 mg single dose, effective up to 120 hours post-intercourse) and for managing abnormal uterine bleeding (AUB) in leiomyoma patients. Retrieved Imperial College London and All India Institute of Medical Sciences papers provide clinical use context, including comparisons with levonorgestrel for emergency contraception and weight-related efficacy differences in patients over 75 kg.
The AMH-based contraceptive patents by La Marca (active IT jurisdiction) and the Drosophila-based follicle rupture screening platform from Northwestern University together signal two early-stage but mechanistically orthogonal directions for non-hormonal female contraception — each potentially addressable by small molecules or biologics — warranting IP landscaping and target validation investment. The Northwestern platform screened 1,172 FDA-approved drugs, identifying six compounds with dose-dependent inhibition of follicle rupture.
Still have questions? Let PatSnap Eureka search the contraception patent and literature database for you.
Ask Eureka AI About Contraception R&DAccelerate Your Contraception Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, identify targets, and track clinical signals across the reproductive health pipeline.
References
- Toward Development of the Male Pill: A Decade of Potential Non-hormonal Contraceptive Targets — University of Houston–Clear Lake, 2020
- Optimization of lead compounds into on-demand, nonhormonal contraceptives: leveraging a public–private drug discovery institute collaboration — Weill Cornell Medicine, 2020
- Retinoic acid receptor antagonists for male contraception: current status — University of Minnesota, 2020
- Epididymal approaches to male contraception — CNRS/University of Clermont Auvergne, 2018
- Hormonal Male Contraception: Getting to Market — NIH/Eunice Kennedy Shriver NICHD, 2022
- Male Hormonal Contraception: Where Are We Now? — Harbor-UCLA Medical Center, 2016
- Engineering highly multivalent sperm-binding IgG antibodies for potent non-hormonal female contraception — University of North Carolina at Chapel Hill, 2020
- Engineering monoclonal antibody-based contraception and multipurpose prevention technologies — ZabBio, Inc., 2020
- A platform utilizing Drosophila ovulation for nonhormonal contraceptive screening — Northwestern University, 2021
- Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products — Midwestern University, 2022
- Immunocontraceptives: New Approaches to Fertility Control — Panjab University, 2014
- Polyacrylate-GnRH Peptide Conjugate as an Oral Contraceptive Vaccine Candidate — University of Queensland, 2021
- 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies — Imperial College London, 2020
- WHO Reproductive Health and Research — Global contraception data and family planning statistics
- NIH National Institutes of Health — Reproductive medicine and contraceptive research funding
- U.S. Food and Drug Administration — Contraceptive drug approvals and regulatory guidance
- European Medicines Agency — SPRM and contraceptive product regulatory assessments
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a targeted patent and literature dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.